184 related articles for article (PubMed ID: 35277863)
21. Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.
Taleban S; Li D; Targan SR; Ippoliti A; Brant SR; Cho JH; Duerr RH; Rioux JD; Silverberg MS; Vasiliauskas EA; Rotter JI; Haritunians T; Shih DQ; Dubinsky M; Melmed GY; McGovern DP
J Crohns Colitis; 2016 Jan; 10(1):43-9. PubMed ID: 26449790
[TBL] [Abstract][Full Text] [Related]
22. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.
Jansen FM; Vavricka SR; den Broeder AA; de Jong EM; Hoentjen F; van Dop WA
United European Gastroenterol J; 2020 Nov; 8(9):1031-1044. PubMed ID: 32921269
[TBL] [Abstract][Full Text] [Related]
23. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes.
Orchard TR; Chua CN; Ahmad T; Cheng H; Welsh KI; Jewell DP
Gastroenterology; 2002 Sep; 123(3):714-8. PubMed ID: 12198697
[TBL] [Abstract][Full Text] [Related]
24. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of cytapheresis for induction therapy and extra-intestinal skin manifestations of ulcerative colitis.
Shibuya T; Nomura O; Nomura K; Haraikawa M; Haga K; Ishikawa D; Osada T; Yamaji K; Ikeda S; Nagahara A
Ther Apher Dial; 2022 Jun; 26(3):522-528. PubMed ID: 35247233
[TBL] [Abstract][Full Text] [Related]
27. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.
Weizman A; Huang B; Berel D; Targan SR; Dubinsky M; Fleshner P; Ippoliti A; Kaur M; Panikkath D; Brant S; Oikonomou I; Duerr R; Rioux J; Silverberg M; Rotter JI; Vasiliauskas E; Haritunians T; Shih D; Li D; Melmed GY; McGovern DP
Inflamm Bowel Dis; 2014 Mar; 20(3):525-33. PubMed ID: 24487271
[TBL] [Abstract][Full Text] [Related]
28. Dermatological signs during inflammatory bowel diseases.
Feliciani C; De Simone C; Amerio P
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():15-21. PubMed ID: 19530507
[TBL] [Abstract][Full Text] [Related]
29. Peripheral arthritis in the course of inflammatory bowel diseases.
Yüksel I; Ataseven H; Başar O; Köklü S; Ertuğrul I; Ulker A; Dağlı U; Saşmaz N
Dig Dis Sci; 2011 Jan; 56(1):183-7. PubMed ID: 20458624
[TBL] [Abstract][Full Text] [Related]
30. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
31. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.
Atzeni F; Ardizzone S; Bertani L; Antivalle M; Batticciotto A; Sarzi-Puttini P
World J Gastroenterol; 2009 May; 15(20):2469-71. PubMed ID: 19468996
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Siemanowski B; Regueiro M
Curr Treat Options Gastroenterol; 2007 Jun; 10(3):178-84. PubMed ID: 17547856
[TBL] [Abstract][Full Text] [Related]
33. Treatment of pyoderma gangrenosum, erythema nodosum, and aphthous ulcerations.
Winter HS
Inflamm Bowel Dis; 1998 Feb; 4(1):71. PubMed ID: 9552232
[No Abstract] [Full Text] [Related]
34. Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
States V; O'Brien S; Rai JP; Roberts HL; Paas M; Feagins K; Pierce EJ; Baumgartner RN; Galandiuk S
Dig Dis Sci; 2020 Sep; 65(9):2675-2685. PubMed ID: 31925675
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
Ramos GP; Dimopoulos C; McDonald NM; Janssens LP; Hung KW; Proctor D; Ruggiero E; Kane S; Bruining DH; Faubion WA; Raffals LE; Loftus EV; Al-Bawardy B
Inflamm Bowel Dis; 2021 Jul; 27(8):1270-1276. PubMed ID: 33165569
[TBL] [Abstract][Full Text] [Related]
36. Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients.
Bandyopadhyay D; Bandyopadhyay S; Ghosh P; De A; Bhattacharya A; Dhali GK; Das K
Indian J Gastroenterol; 2015 Sep; 34(5):387-94. PubMed ID: 26614005
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
38. [Extra-intestinal manifestation of IBD in Veszprém county (of Hungary): results of a 25-years follow-up study].
Lakatos L; Pandur T; Dávid G; Balogh Z; Küronya P; Tollas A; Lakatos PL
Orv Hetil; 2003 Oct; 144(40):1965-75. PubMed ID: 14626638
[TBL] [Abstract][Full Text] [Related]
39. Mucocutaneous manifestations in inflammatory bowel disease.
Yüksel I; Başar O; Ataseven H; Ertuğrul I; Arhan M; Ibiş M; Dağli U; Demirel BT; Ulker A; Seçilmiş S; Saşmaz N
Inflamm Bowel Dis; 2009 Apr; 15(4):546-50. PubMed ID: 19023896
[TBL] [Abstract][Full Text] [Related]
40. Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.
Greuter T; Vavricka SR
Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):307-317. PubMed ID: 30791773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
